Subsequent denosumab doses were associated with lower risks for hypocalcemia among patients with osteoporosis and chronic kidney disease . Magnitude of serum calcium decrease is smaller with ...

Please provide your email address to receive an email when new articles are posted on . The FDA issued a boxed warning stating denosumab increases severe hypocalcemia risk for adults with advanced CKD ...

Many women on dialysis quickly developed severe hypocalcemia after starting denosumab (Prolia) for osteoporosis, Medicare data showed. During the first 12 weeks of treatment, 41.1% of women on ...

The FDA has added a serious warning to the prescribing information for Amgen Inc’s (NASDAQ:AMGN) drug Prolia (denosumab), emphasizing an increased risk of severely low calcium levels in specific ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

The US Food and Drug Administration (FDA) has added a boxed warning to the label of the osteoporosis drug denosumab (Prolia) about increased risk for severe hypocalcemia in patients with advanced ...

Findings showed treatment with Prolia significantly increased the risk of developing severe hypocalcemia compared with bisphosphonates, especially in patients with advanced CKD. In patients with ...

FDA’s boxed warning on denosumab follows study results showing increased and early risks of severe hypocalcemia in patients on dialysis. The Food and Drug Administration (FDA) has added a new boxed ...

The FDA will investigate the risk of severe hypocalcemia that results in hospitalization and death with Amgen’s osteoporosis drug, Prolia (denosumab). Ongoing safety research on Prolia suggests an ...

Panel A shows the changes in the levels of the bone-formation marker procollagen type 1 N-terminal propeptide (P1NP) and the levels of the bone-resorption marker C-terminal telopeptide (CTX) in each ...